Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2019 Aug 8;18(10):1800–1810. doi: 10.1158/1535-7163.MCT-19-0046

Figure 4.

Figure 4.

Leelamine (LLM) administration downregulated protein level of ATP citrate lyase (ACLY) and suppressed accumulation of neutral lipid droplets in 22Rv1 xenografts in vivo. A, Western blotting for ACLY, acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN) proteins using supernatants from 22Rv1 xenografts from control (n=6) and LLM-treated mice (n=5). B, Densitometric quantitation of the ACLY, ACC1 and FASN expression in 22Rv1 xenografts. The results shown are mean ± SD. *Statistically significant (P<0.05) compared with control by Student’s t-test. C, Immunohistochemistry for ACLY, ACC1, and FASN protein expression in a representative 22Rv1 xenograft section of the control mouse and that of LLM-treated mouse (×400 magnification, scale bar= 50 μm). D, Quantitation of ACLY, ACC1, and FASN expression (H-score). The results shown are mean ± SD. *Statistically significant (P<0.05) compared with control by Student’s t-test. E, Representative confocal microscopy images for BODIPY staining depicting neutral lipid droplets in a representative 22Rv1 xenograft section of a control mouse and that of a LLM-treated mouse. F, Quantitation of the number of lipid droplets/cell in the tumors of control- and LLM-treated mice. Results shown are mean ± SD (n=5–6). *Statistically significant (P<0.05) compared with control by Student’s t-test.